NEW YORK (GenomeWeb News) – Agilent Technologies said today that it has entered into a co-marketing agreement with MRM Proteomics that will enable the firms to offer more complete hardware, software, and proteomics kit solutions.
Vancouver-based MRM provides protein quantitation, biomarker, and proteomic services to pharmaceutical, biotech, and diagnostics customers. The company specializes in providing highly multiplexed quantitation of proteins in biosamples from blood, cerebrospinal fluid, and urine, using isotopically labeled internal standards.
"The agreement is a further reflection of Agilent's continued commitment and investment in quantitative proteomics," Agilent Metabolomics and Proteomics Marketing Manager Steve Fischer said in a statement.